论文部分内容阅读
为探讨核黄素对冠心病患者血小板聚集及心功能影响，随机选择冠心病３１２例，分成４组：ＲＢＦｂ组（大剂量核黄素组）、ＲＢＦｓ组（小剂量核黄素组）、ＡＳ组（阿斯匹林组）和Ｃ组（安慰剂，对照组），测量用药前后血小板聚集（ＰＡＴ）与心功能变化。结果发现大剂量核黄素有显著抗血小板聚集作用，且强于阿斯匹林，二组比较Ｐｔｍａｘ（最大聚集强度）和ＰｔＫ（聚集速率）有显著差异（Ｐ＜００５），并显示明显改善心功能的作用。作者认为核黄素可作为冠心病的二级预防药。
To investigate the effect of riboflavin on platelet aggregation and cardiac function in patients with coronary heart disease, 312 patients were randomly divided into 4 groups: RBFb group (high-dose riboflavin group), RBFs group (low-dose riboflavin group), AS Group (aspirin group) and group C (placebo, control group), before and after treatment of platelet aggregation (PAT) and cardiac function changes. The results showed that high doses of riboflavin had a significant anti-platelet aggregation effect and stronger than aspirin. There was significant difference (P <005) between Ptmax (maximum aggregation intensity) and PtK (aggregation rate) in the two groups Significantly improve the function of heart function. The authors believe that riboflavin can be used as secondary prevention of coronary heart disease drugs.